Patients with end-stage liver disease are at risk of cardiac and hemodynamic complications such as cirrhotic cardiomyopathy, pulmonary hypertension (PH), hepatopulmonary syndrome, and hepatorenal syndrome related to hyperdynamic state, increased venous volume, and decreased systemic vascular resistance. (1, 2) Therefore, hemodynamic monitoring during the preoperative and intraoperative period is crucial for liver transplantation (LT) recipients.
Original article | 1681

Patients and Methods
stUDY POPUlatiOn anD Data cOllectiOn
The present study used a single-center LT database. From January 2011 to May 2016, 507 consecutive recipients with intraoperative RHC were initially enrolled in our registry. The exclusion criteria included the following:
1. Age under 18 years. 2. Multiple organ transplantations. 3. Lack of PVR measurement due to hemodynamic instability or arrhythmia.
Finally, 363 recipients remained for analysis. Clinical, laboratory, and outcome data were collected by a trained study coordinator using a standardized case report protocol. All participants were deidentified and analyzed anonymously. This study was approved by an institutional review board, and the need for individual consent was waived.
DeFinitiOn anD OUtcOMes
The primary outcome was death or graft failure, which is defined as a composite of all-cause death and retransplantation during the overall follow-up period. The secondary outcomes were (a) death or graft failure during an in-hospital stay and (b) a composite of severe complications according to the Clavien-Dindo classification of an in-hospital stay and the follow-up period. Clavien-Dindo classification was briefly defined as follows: IIIb, complications requiring interventions under general anesthesia; IV, life-threatening complications; and V, death. (8) Cirrhotic cardiomyopathy was defined according to recently proposed criteria. (9) Cardiac dysfunctions were defined based on preoperative echocardiography. Systolic dysfunction was defined as an ejection fraction <55%, and diastolic dysfunction was defined according to the E/A ratio, E', and the left atrial volume index. (10) Diabetes mellitus was defined as having a history of diagnosis of diabetes mellitus and undergoing treatment either pharmacologically or by lifestyle intervention. Hypertension was defined as either self-reported use of antihypertensive medications or defined as resting systolic blood pressure >140 mm Hg. Smoking history was reported as at least a 10 pack-year history of tobacco use. Chronic obstructive pulmonary disease was defined as any state of disease characterized by airflow limitation. Change in hemodynamic parameters during surgery was determined as the difference between the lowest and highest values.
HeMODYnaMic ParaMeters
Preoperative evaluation included echocardiography in all candidates. Candidates with increased pulmonary arterial pressure on preoperative echocardiography were treated with vasodilatory drugs before LT. Intraoperative RHC with a Swan-Ganz catheter (Edward Lifesciences LLC, Irvine, CA) was selectively performed with consideration of the risk of bleeding and arrhythmia. (11) After direct cannulations, standard pressure measurements were automatically made using an electronic transducer (Edward Lifesciences LLC). Hemodynamic parameters were measured at specified time points according to the phase of LT: every hour starting from immediately after induction of general anesthesia before surgical incision, every hour starting from the beginning of the anhepatic phase, at reperfusion, 5 and 30 minutes after reperfusion, and every hour after reperfusion until the end of the procedure. The mechanical ventilator was temporarily turned off for measurements, and all results were recorded by attending anesthesiologists. PVR was retrospectively calculated by a single blinded investigator using the equation below (mean pulmonary arterial pressure [mPAP]; pulmonary capillary wedge pressure [PCWP] ). (12) PVR = (mPAP -PCWP) × 80/cardiac output Increased PVR was defined as over 130 dyne seconds/cm -5 , which is a normal limit among the healthy population. (4, 13) Recipients were categorized according to PVR (normal PVR versus increased PVR). Two separate analyses were made at distinct time points of measurement: at the beginning and at the end of the procedure. The beginning was defined as immediately after induction of general anesthesia and before surgical incision, and the end was defined as the last measurement. Both time points were selected to minimize the effect of surgical stress on hemodynamic parameters. Clinical outcomes between the 2 groups of each time point were independently compared to evaluate the association with increased PVR at different phases of LT.
anestHetic anD sUrgical ManageMent
Standardized anesthetic management of our institution has been described elsewhere. (14) Standard monitoring devices (peripheral capillary oxygen saturation, 5-lead electrocardiogram, and noninvasive arterial blood pressure) were applied, and the recipients were induced with thiopental sodium (5 mg/kg) and maintained with isoflurane titrated to a bispectral index of 40-60. Remifentanil was infused up to 0.20 µg/kg/minute in response to hemodynamic changes. Mechanical ventilation was set to achieve normocapnia at a tidal volume of 8-10 mL/kg using a mixture of medical air and oxygen at a fresh gas flow rate of 2 L/ minute. The radial artery, femoral artery, femoral vein, and internal jugular vein were cannulated for real-time and direct monitoring of hemodynamic parameters. Intravenous fluids and pressor drugs, such as norepinephrine, vasopressin, and dopamine, were infused to maintain mean arterial pressure ≥70 mm Hg. A warm blanket and a fluid warmer were used to maintain normothermia. Packed red blood cells were transfused when blood hemoglobin concentration was <8.0 mg/ dL. All surgical procedures were performed in accordance with the standardized institutional protocol.
statistical analYsis
We compared continuous variables using the t test or the Wilcoxon rank sum test when applicable and presented as the mean ± standard deviation (SD) or median with interquartile range (IQR). Comparisons of categorical variables were made by chi-square or Fisher's exact test. Survival curves were generated using Kaplan-Meier estimates and compared with the log-rank test. The variables that are clinically relevant or showed P < 0.15 were adjusted in the multivariate model. The adjusted hazard ratio (HR) and 95% confidence interval (CI) were compared using Cox regression based on the following variables: age, male, living donor, smoking, previous use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), hepatocellular carcinoma, liver cirrhosis, acute hepatic failure, alcohol-related disease, hepatitis B virus (HBV)-related disease, hepatorenal syndrome, Model for End-Stage Liver Disease (MELD) score, and use of pressor drugs at measurement. For further analysis, we used logistic regression analysis to evaluate the association between homodynamic parameters and primary outcome. Statistical analyses were performed with IBM SPSS, version 20.0.0 (IBM, Armonk, NY) and R, version 3.4 (R Foundation, Vienna, Austria). All tests were 2-tailed, and P < 0.05 was considered statistically significant.
Results
A total of 363 recipients were enrolled in the present study, and the median follow-up period was 29.2 months (IQR, 11.4-54.1 months). Figure 1 shows a flowchart of the enrolled recipients. The clinical outcomes of recipients who were excluded due to the absence of PVR measurement are summarized in Supporting Text 1. We performed 2 separate analyses according to the time point of PVR measurement (at the beginning and at the end of LT). Among 363 recipients, 320 (88.2%) showed normal PVR, and 43 (11.8%) showed increased PVR at the beginning of LT. The mean PVR was 54.0 (±29.4) dyne seconds/ Original article | 1683 cm -5 in the normal group and 187.1 (±59.4) dyne seconds/cm -5 in the increased PVR group (P < 0.001). At the end of LT, 317 (87.3%) recipients showed normal PVR, and 46 (12.7%) showed increased PVR. The mean PVR was 58.9 (±28.1) dyne seconds/cm -5 in the normal group and 210.0 (±98.7) dyne seconds/cm -5 in the increased PVR group (P < 0.001).
Pvr at tHe Beginning OF lt: nOrMal versUs increaseD
The baseline characteristics are described in Table 1 . Recipients with increased PVR were older, more frequently used preoperative ACEi/ARB, and showed lower incidence of cirrhotic disease and higher incidence of acute hepatic failure. On preoperative evaluation, recipients with increased PVR had a higher MELD score. The increased PVR group showed a greater change in PVR during surgery. At the time of point of PVR measurement, hemodynamic parameters on RHC showed higher mPAP and systemic vascular resistance and lower PCWP. There was no statistical difference in requirements for pressor drug infusion at PVR measurement. In the multivariate analysis, there was no significant difference in the incidence of death or graft failure between the normal and the increased PVR groups at the beginning of LT (HR, 1.24; 95% CI, 0.64-2.38; P = 0.52; Table 2 ; Fig. 2A ). Duration of intensive care unit (ICU) stay was significantly longer in the increased PVR group (7.7 versus 11.0 days, P = 0.04).
Pvr at tHe enD OF lt: nOrMal versUs increaseD Table 3 summarizes baseline characteristics between the 2 groups stratified according to PVR at the end of LT. Recipients with increased PVR showed a lower incidences of male sex, living donor, hepatocellular carcinoma, and cirrhotic disease and a higher incidence of acute hepatic failure and hepatorenal Original article | 1685 syndrome. On preoperative evaluation, the increased PVR group showed higher MELD scores. The change in PVR during surgery was greater in the increased PVR group. Other hemodynamic parameters measured by RHC such as central venous pressure, mPAP, and systemic vascular resistance were higher in the increased PVR group. The requirement for pressor drug infusion at measurement was also higher in the increased PVR group. In the multivariate analysis, the incidences of overall death or graft failure and Clavien-Dindo IV-V complications during the in-hospital stay and overall follow-up period were higher in the increased PVR group (HR, 2.00; 95% CI, 1.13-3.54; P = 0.02; HR, 1.87; 95% CI, 1.02-3.45; P = 0.04; HR, 2.77; 95% CI, 1.22-6.29; P = 0.02, respectively; Table 4 ; Fig. 2B ).
cHange in Pvr DUring lt
In further analyses, only PVR measured at the end of LT was significantly associated with death or graft failure (odds ratio, 1.01; 95% CI, 1.00-1.01; P = 0.001; Table 5 ). The changes in PVR at each phase of LT (beginning, anhepatic, reperfusion, and end) are shown in Supporting Texts 2 and 3. During LT, the normal PVR group showed an increase in PVR above the normal level in 28/320 (8.8%) recipients, and the increased PVR group showed normalization of PVR in 25/43 (58.1%) recipients. All recipients were divided into 4 groups according to the change in PVR during LT: no change of normal PVR (292, 80.4%), increased to normal PVR (25, 6.9%), normal to increased PVR (28, 7.7%), and persistently increased PVR (18, 5.0%) ( Fig. 1; Supporting Text 4) . Figure 3 shows the survival curves of the 4 groups. Within normal PVR groups, the normal to increased group showed a significant difference from the normal group with no changes (P = 0.02). The incidence and causes of deaths in 4 groups are summarized in Supporting Text 4. Although it was not statistically significant, the normal to increased PVR group showed the highest mortality rate. All 6 deaths in the persistently increased PVR group occurred within the hospital stay. Cardiovascular complications during the hospital stay in recipients with increased PVR at the end of LT are presented in Supporting Text 5. NOTE: Values are n (%) or mean (±SD). Covariates include age, male, living donor, previous use of ACEi/ARB, hepatocellular carcinoma, liver cirrhosis, acute hepatic failure, alcohol-related, HBV-related, hepatorenal syndrome, MELD score, PVR change, and infusion of pressor drugs at measurement. Original article | 1687
Discussion
The main findings of this study are as follows:
1. Increased PVR was obeserved in recipients undergoing LT (11.8% at the beginning; 12.7% at the end), even after preoperative vasodilatory therapy in recipients with PH. 2. PVR at the end of LT, rather than at the beginning, was associated with adverse clinical outcomes.
These results suggest the clinical value of measuring intraoperative PVR during LT.
Cardiovascular involvement of end-stage liver disease is well recognized to be associated with adverse outcomes. (15) It is characterized by specific cardiovascular responses such as increased cardiac output and a compromised ventricular response to stress. Proposed causes for these disturbances include decreased betaagonist transduction, increased circulating inflammatory mediators with cardiodepressant properties, and repolarization changes. (9, 16, 17) Given these underlying pathophysiologies, pulmonary hemodynamic status is associated with the clinical outcome of LT. (18) Among hemodynamic parameters, PVR distinguishes 2 well-known pulmonary syndromes of end-stage liver disease that show distinct clinical consequnces of LT: portopulmonary hypertension (POPH) and hepatopulmonary syndrome. Although LT is considered to be curative for hepatopulmonary syndrome without PVR elevation, (12) the safety of LT is still controversial for candidates with even mild to moderate POPH. (19, 20) Although it was once considered a contraindication for LT, previous studies have reported favorable outcomes in recipients with mild POPH (mPAP < 35 mm Hg) or those who had responded well to preoperative vasodilating treatment. (21, 22) Therefore, a recent study suggested measuring preoperative PVR in recipients with moderate PH. (12) However, unlike other complications that have been shown to be reversed by LT such as cirrhotic cardiomyopathy or hepatopulmonary syndrome, (8) there are limited data on PVR of LT recipients. The present study showed that PVR was increased above the normal limit in 11.8% (43/363) of all recipients even after preoperative vasodilating treatment among recipients with PH because the diagnostic criteria of PVR for POPH (over 240 dyne seconds/ cm -5 ) is higher than the normal limit of healthy population. (4, 12, 13) Among recipients with increased PVR, normalization during LT was observed in 25 (58.1%), but whether this change in PVR is associated with clinical outcomes is uncertain. Therefore, we hypothesized that intraoperative PVR is associated with clinical outcome of LT, and by extension, we also evaluated whether LT affects PVR by reversing hemodynamic features of end-stage liver disease.
Comparisons of baseline characteristics showed different results among separate analyses according to the time point of measurement. At the beginning of LT, the difference in PVR was shown to be dependent on age, preoperative ACEi/ARB use, MELD score, cirrhotic disease, and acute hepatic failure. Higher age, MELD score, and incidence of acute hepatic failure suggested acutely ill recipients with poor conditions in the increased PVR group, and we assumed that PVR at the beginning of LT reflects the preoperative state of the recipient. However, the relationship between PVR and other variables such as etiology and previous medication use has not yet been fully determined. The increased PVR group at the end of LT showed a lower incidence of living donor, even though a small-forsize graft is a risk factor of portal hypertension. (23, 24) This may be explained by the fact that nearly all of our grafts from living donors were the right lobe (V-VIII). Infusion of pressor drugs at the end of LT was more frequent in the increased PVR group, which might suggest cardiovascular instability related to the recipient's poor condition. However, it is unlikely that PVR was increased by the use of pressor drugs because we used norepinephrine, vasopressin, and dopamine, according to institutional protocol, and these agents are all known to have minimal effects on PVR. (25) (26) (27) Moreover, norepeinephrine, which was our primary pressor drug, has even shown a pulmonary vasodilator effect in an animal study. (28) The present study showed that increased PVR at the beginning of LT was not associated with adverse outcomes. Inconsistencies with previous studies on other pulmonary hemodynamic parameters may be explained as follows. (29) First, patients with extremely high mPAP were not allocated for LT according to our institutional protocol. As a result, this study did not include any participants with extremely high PVR. Exclusion of patients with severe PH might have affected the results by decreasing overall mortality. (4, 5) Second, normalization of PVR during LT may have also affected the outcome. In this study, more than half of the recipients (58.1%) with increased PVR at the beginning of LT showed normalized PVR after LT, and the incidence of adverse outcomes in these recipients was lower than in recipients with increased PVR at the end of LT. Further investigations into this phenomenon are needed.
PVR at the end of LT was associated with death or graft failure during the follow-up period and with postoperative life-threatening complications, but not with immediate operative complications. This is concordant with our hypothesis in that PVR at the end of LT reflects the quality of the graft organ rather than complications associated with the surgical process. We speculate that an improved PVR after LT is due to successful reversal of hemodynamic features of end-stage liver disease. However, the exact mechanism of PVR changes during LT cannot be determined from this study. Recipients with persistently increased or worsened (normal to increased) PVR showed a higher mortality rate compared with recipients with normal or improved (increased to normal) PVR. Although the difference in outcomes between worsened and improved PVR groups showed inconsistent results, the persistently increased PVR group showed longer durations of hospital and ICU stay, and every mortality in this group occurred during the hospital stay. The precise cause of these deaths requires further investigation with a larger number of participants.
This study should be appraised in the light of the following limitations. This study is not a randomized trial, and therefore, potential confounding factors or selection bias might have affected the results. On the basis of the current guidelines, candidates with high mPAP are preoperatively treated with vasodilatory therapy, and only those who respond well are recommended for LT. Therefore, recipients allocated for LT might be expected to have a low incidence of increased PVR, and the extent of hyperdynamic circulation could not be evaluated in this study. Another limitation is the variation in the duration from organ reperfusion to the end of LT. The time period from organ reperfusion to measurement might affect the state of the graft organ. The present study did not reveal the mechanism or clinical benefit of managing PVR during LT. Moreover, there is no consensus on the optimal hemodynamic management during LT. (29, 30) Because of these limitations, the results of this study are not confirmative. Nonetheless, this is the first to provide data on the clinical value of intraoperative PVR measurement during LT and to suggest PVR as an intraoperative hemodynamic parameter that should be carefully investigated.
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In conclusion, in recipients undergoing LT, PVR at the end of the procedure rather than the beginning is associated with adverse outcomes. Larger registry data sets are needed to support this finding.
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